SCHEMBL2567526

SCHEMBL2567526

COc1ccc(C(OCC2CO2)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
TP53 P04637 3/20 0.48
ALDH1A1 P00352 3/20 0.48
MAPT P10636 2/20 0.48
HPGD P15428 2/20 0.48
TSHR P16473 2/20 0.48
CYP1A2 P05177 2/20 0.48
PPARG P37231 1/20 0.48
HIF1A Q16665 1/20 0.48
TDP1 Q9NUW8 1/20 0.46
PKM P14618 1/20 0.46
SLC6A11 P48066 4/20 0.44
SLC6A1 P30531 2/20 0.44
LMNA P02545 1/20 0.43
KIF11 P52732 2/20 0.42
KCNH2 Q12809 1/20 0.42
TYMP P19971 1/20 0.40
PTPN1 P18031 1/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2567523 1.00 MEN1 (0.57) MEN1KMT2ATP53ALDH1A1MAPT
SCHEMBL27056605 1.00 MEN1 (0.57) MEN1KMT2ATP53ALDH1A1MAPT
SCHEMBL7623595 0.87 TDP1 (0.53) MEN1KMT2ATP53ALDH1A1MAPT
SCHEMBL689297 0.87 TDP1 (0.53) MEN1KMT2ATP53ALDH1A1MAPT
SCHEMBL914084 0.87 TDP1 (0.53) MEN1KMT2ATP53ALDH1A1MAPT
SCHEMBL22879134 0.86 MEN1 (0.43) MEN1KMT2ATP53CYP1A2SLC6A11
SCHEMBL12515630 0.85 HPGD (0.48) MEN1KMT2ATP53ALDH1A1HPGD
SCHEMBL21158798 0.82 SLC6A11 (0.43) MEN1KMT2ATP53CYP1A2SLC6A11
SCHEMBL27414176 0.82 SLC6A11 (0.43) MEN1KMT2ATP53CYP1A2SLC6A11
SCHEMBL5930034 0.81 TYMP (0.42) MEN1KMT2ATP53CYP1A2SLC6A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250302995-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF SHIVALILA CHIKDU SHAKTI (US) 2025-10-02 US disclosed
US-20250262235-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD (SG) 2025-08-21 US disclosed
US-20250135036-A1 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2025-05-01 US disclosed
EP-4522744-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF Wave Life Sciences Ltd. (SG) 2025-03-19 EP disclosed
EP-4507700-A2 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO Wave Life Sciences Ltd. (SG) 2025-02-19 EP disclosed
EP-4404942-A2 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF Wave Life Sciences Ltd. (SG) 2024-07-31 EP disclosed
CN-117304141-B 2S-4,4' -dimethoxy trityl ethylene oxide and preparation method thereof 苏州诺维康生物科技有限公司 2024-02-20 CN disclosed
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
CN-117304141-A 2S-4,4' -dimethoxy trityl ethylene oxide and preparation method thereof 苏州诺维康生物科技有限公司 2023-12-29 CN disclosed
US-20230392137-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-12-07 US disclosed
WO-2023220440-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-11-16 WO disclosed
WO-2023220428-A1 COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-11-16 WO disclosed
WO-2023201095-A2 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-10-19 WO disclosed
EP-4240849-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF Wave Life Sciences Ltd. (SG) 2023-09-13 EP disclosed
WO-2023049477-A2 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-03-30 WO disclosed
WO-2022099159-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2022-05-12 WO disclosed
US-20210087219-A1 OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS ALNYLAM PHARMACEUTICALS INC (US) 2021-03-25 US disclosed
US-10913767-B2 Oligonucleotides comprising acyclic and abasic nucleosides and analogs ALNYLAM PHARMACEUTICALS, INC. (US) 2021-02-09 US disclosed
US-20130130378-A1 OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-05-23 US disclosed
WO-2011133876-A2 OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS ALNYLAM PHARMACEUTICALS, INC. (US) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10913767-B2 Oligonucleotides comprising acyclic and abasic nucleosides and analogs NSUN2, BCDIN3D, ADAR MEN1 2256/4885KMT2A 3068/4885TP53 1452/4885
US-20130130378-A1 OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS ADAR, TYMS, POLM MEN1 2296/4885KMT2A 3042/4885TP53 2279/4885
US-20250302995-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF ADAR, NSUN2, RNGTT MEN1 3166/4885KMT2A 732/4885TP53 620/4885
US-20250262235-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO ADAR, RNGTT, NSUN2 MEN1 3780/4885KMT2A 1961/4885TP53 912/4885
US-20250135036-A1 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF MECP2, ADAR, NSUN2 MEN1 3460/4885KMT2A 171/4885TP53 3665/4885
US-20210087219-A1 OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS NSUN2, BCDIN3D, RNGTT MEN1 2563/4885KMT2A 3169/4885TP53 1874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.